PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

ABSTRACT:

SUBMITTER: Barrientos J 

PROVIDER: S-EPMC9431472 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature